Angiotensin receptor Neprilysin inhibitor: A novel treatment for heart failure with reduced heart failure (HFrEF)
| dc.contributor.advisor | Borbély, Attila | |
| dc.contributor.advisordept | Debreceni Egyetem::Általános Orvostudományi Kar::Kardiológiai Intézet | hu_HU |
| dc.contributor.author | Ehizuenlen, Joy | |
| dc.contributor.department | DE--Általános Orvostudományi Kar | hu_HU |
| dc.contributor.opponent | Kolozsvári, Rudolf | |
| dc.contributor.opponent | Kerekes, György | |
| dc.contributor.opponentdept | Debreceni Egyetem::Általános Orvostudományi Kar::Kardiológiai Intézet | hu_HU |
| dc.contributor.opponentdept | Debreceni Egyetem::Általános Orvostudományi Kar::Belgyógyászati Intézet | hu_HU |
| dc.date.accessioned | 2022-08-29T09:55:17Z | |
| dc.date.available | 2022-08-29T09:55:17Z | |
| dc.date.created | 2021-06-18 | |
| dc.description.abstract | This review aimed to summarize the currently available information on angiotensin receptor neprilysin inhibitor (sacubitril/valsartan, ARNI), a novel therapeutic approach for heart failure with reduced ejection failure (HFrEF). Drug development, pharmacokinetics, molecular and hemodynamic effects and clinical effects of ARNI were discussed | hu_HU |
| dc.description.course | általános orvos | hu_HU |
| dc.description.courselang | angol | hu_HU |
| dc.description.degree | egységes, osztatlan | hu_HU |
| dc.format.extent | 38 | hu_HU |
| dc.identifier.uri | http://hdl.handle.net/2437/336889 | |
| dc.language.iso | en | hu_HU |
| dc.subject | Heart failure | hu_HU |
| dc.subject | ARNI | |
| dc.subject.dspace | DEENK Témalista::Orvostudomány | hu_HU |
| dc.title | Angiotensin receptor Neprilysin inhibitor: A novel treatment for heart failure with reduced heart failure (HFrEF) | hu_HU |